Eli Lilly and Co at Guggenheim Biopharma's Next Decade Virtual Conference Transcript
Okay. It looks like we are on to the second discussion today. Earlier, we had Novo Nordisk as part of our discussion. And this is a really exciting opportunity for us. I just want to thank everybody for joining us here today. It's a 50-minute discussion with Eli Lilly's Chief Scientific Officer, Dan Skovronsky. I'm Seamus Fernandez. Many of you know me. I'm one of the senior therapeutic analyst here at Guggenheim. And I'm really pleased that we've got Dan for this unique strategy series, which is really just focusing on the innovation and strategies that biopharma companies are -- obviously employment benefit patients, but also to drive growth over the next decade or 2. So really excited to have Dan here with us. Thanks so much again.
Before we dive into questions, I'm just going to give a very quick background of Dr. Skovronsky here. Many of you know Dan as the Chief Scientific and Medical Officer of Eli Lilly. He serves as the Senior Vice President of Science and Technology and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
